Cromos Pharma

Cromos Pharma Cromos Pharma is an international research organization (CRO) specializing in clinical trials. Find out more by visiting www.cromospharma.com.

Established in 2004, Cromos Pharma provides tailored and effective clinical trial services to support the development of drugs that transform healthcare. It is an international CRO with over 15 years' experience in offering fully integrated services and delivering all aspects of clinical trials in all clinical phases and a range of therapeutic areas. Cromos Pharma delivers rapid recruitment and excellent patient retention as well as expert study design and management. Cromos Pharma has strong regional experience in Central and Eastern Europe. Its US base is in Portland, Oregon with additional operations in South Florida and its European HQ is situated in Dublin, Ireland.

10/31/2025

Happy Halloween from all of us at Cromos Pharma! 🎃

Here’s to a night full of fun, surprises, and sweet treats.
Stay spooky, stay safe — and enjoy every moment!

In today’s complex regulatory environment, every submission counts. From FDA INDs and NDAs to EMA CTIS and PRIME program...
10/30/2025

In today’s complex regulatory environment, every submission counts. From FDA INDs and NDAs to EMA CTIS and PRIME programs, success depends on mastering diverse frameworks while keeping timelines on track.

At Cromos Pharma, our Regulatory Affairs team bridges global strategy and local expertise — helping sponsors align documentation, accelerate reviews, and achieve first-cycle approvals across the U.S., EU, and emerging markets.

Learn more about our global regulatory expertise and how we help sponsors navigate multi-jurisdictional submissions efficiently: https://cromospharma.com/cro-regulatory-affairs-bridging-strategy-compliance-and-speed/

At this year’s ESMO Congress in Berlin, over 35,000 oncology professionals gathered to explore data that will shape the ...
10/28/2025

At this year’s ESMO Congress in Berlin, over 35,000 oncology professionals gathered to explore data that will shape the next era of cancer research.

Vlad Bogin, MD, FACP, CEO of Cromos Pharma, shares his expert takeaways from the meeting — highlighting breakthroughs that are poised to redefine oncology in 2026 and beyond.

From ADCs entering the curative setting to radioligand therapies moving upstream, Dr. Bogin offers a clear perspective on what these advances mean for sponsors, investigators, and patients alike.

Learn more: https://cromospharma.com/esmo-2025-insights-from-the-floor-what-will-really-change-oncology-in-2026/?preview_id=10605&preview_nonce=ef15f96b45&_thumbnail_id=10606&preview=true

Researchers at Zhejiang University’s Sir Run Run Shaw Hospital have developed Bone-02, a biomimetic “bone glue” that can...
10/22/2025

Researchers at Zhejiang University’s Sir Run Run Shaw Hospital have developed Bone-02, a biomimetic “bone glue” that can repair complex fractures in just three minutes. Inspired by oysters’ ability to adhere to rocks underwater, it enables precise, minimally invasive bone repair and could transform orthopedic surgery.

Such innovations illustrate how biomimicry and clinical research together drive the next generation of regenerative medicine.

Read more here: https://cromospharma.com/from-oysters-to-orthopedics-china-s-bone-02-bio-glue-redefines-fracture-repair/?preview_id=10579&preview_nonce=a0e6773562&_thumbnail_id=10580&preview=true

We’re pleased to share that Vlad Bogin, MD, FACP, CEO of Cromos Pharma, has been attending the ESMO Congress 2025, held ...
10/21/2025

We’re pleased to share that Vlad Bogin, MD, FACP, CEO of Cromos Pharma, has been attending the ESMO Congress 2025, held October 17–21 in Berlin, Germany.

As the event concludes today, Dr. Bogin reflects on a productive week of connecting with global oncology leaders, discussing breakthroughs, and highlighting Cromos Pharma’s dedication to advancing cancer research.

Following our tradition of sharing concise and engaging explainers about key clinical and pharma concepts, we’re continu...
10/21/2025

Following our tradition of sharing concise and engaging explainers about key clinical and pharma concepts, we’re continuing our Pharma Lingo series with a new short video, this time exploring the role of sensitivity, specificity, and predictive values in clinical testing.

Understanding these measures is essential for interpreting diagnostic accuracy and clinical decision-making.

We hope you find this video useful and we’d love to hear your suggestions on other topics you’d like us to cover in future Pharma Lingo episodes:https://cromospharma.com/from-numbers-to-meaning-sensitivity-specificity-predictive-value/

In the October edition of Cromos Pharma’s Newsletter, we highlight key breakthroughs and insights shaping clinical resea...
10/07/2025

In the October edition of Cromos Pharma’s Newsletter, we highlight key breakthroughs and insights shaping clinical research:

– Cromos Pharma Experts Lead Successful “Mastering CTIS” Webinar: Practical strategies for multi-country submissions, compliance, and operational excellence under the EU CTR.
– FDA Grants First-Ever Treatment Approval for Barth Syndrome: Forzinity (elamipretide) offers new hope for patients with this ultra-rare mitochondrial disorder.
– ISO 9001:2015 and ICH GCP E6(R3): How integrating two gold standards builds one language of quality, governance, and patient protection in clinical research.

Read the full October Newsletter here: https://cromospharma.com/clinical-research-focus-45th-edition/

Recently, we published an article exploring why ISO 9001 and GCP integration is becoming a non-negotiable standard for C...
09/29/2025

Recently, we published an article exploring why ISO 9001 and GCP integration is becoming a non-negotiable standard for CROs. The piece highlights how sponsors are raising expectations — demanding not just compliance, but built-in quality systems, risk management, and operational transparency.

For more context, read the full article here: https://cromospharma.com/iso-9001-2015-and-ich-gcp-e6-r3-two-standards-one-language-of-quality-in-clinical-research/

To understand how the industry sees this shift, we ran a poll asking:
"In 5 years, will CROs without ISO + GCP integration still be competitive?"

The response was clear: over 90% believe integration is essential. This supports our view — compliance alone is no longer enough; proactive quality is now the baseline.

Thanks to everyone who shared their perspective.

Our webinar “From Confusion to Confidence: Mastering EU CTR/CTIS” has taken place! Thank you to everyone who joined us. ...
09/25/2025

Our webinar “From Confusion to Confidence: Mastering EU CTR/CTIS” has taken place!

Thank you to everyone who joined us. For those who couldn’t attend — we’ve made all resources available for you:

-Watch the full webinar recording
-Download the presentation slides
-Read the Q&A section with answers to the most popular questions from the live session

All resources are available in one place here: https://lnkd.in/eGyAKzc5

We hope you find these insights useful as you navigate EU CTR/CTIS requirements.

Address

US Bancorp Tower, 111 S. W. Fifth Avenue, Suite 3150
Portland, OR
97204

Telephone

+15034443463

Website

Alerts

Be the first to know and let us send you an email when Cromos Pharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram